Yancai Sun

Yancai Sun


Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 September 2021 in European Journal of Pharmacology
Verified
Journal Article
Closed access
YWYinghong Wang
Yinghong Wang
JZJin Zhang
Jin Zhang
PJPeng Jiang
Peng Jiang
KLKai Li
Kai Li
YSYancai Sun
Yancai Sun
YHYan Huang
Yan Huang

7 October 2022 in Biomedicine & Pharmacotherapy
Verified
Journal Article
Open access
YWYinghong Wang
Yinghong Wang
HZHong Zhou
Hong Zhou
YSYancai Sun
Yancai Sun
YHYan Huang
Yan Huang
Acidic extracellular pH is a major characteristic of tumor tissue, studies suggest that the local pH value of malignant tumor tissues is between 6.0 and 6.9. Acid-sensing ion channel 1 (ASIC1) is proton-gated cation channel activated by low extracellular pH, recently an increasing number of studies have suggested that ASIC1 is involved in different kinds of tumors, which plays an important role in the occurrence and development of tumors. Therefore, this review will summarize studies involved in ASIC1 on tumors and discuss the effect and mechanism of ASIC1 in numerous related tumors, which will provide new perspectives for tumor therapeutic targets.

5 April 2022 in Frontiers in Immunology
Verified
Journal Article
Open access
HZHong Zhou
Hong Zhou
WNWeijian Ni
Weijian Ni
WHWei Huang
Wei Huang
ZWZhen Wang
Zhen Wang
MCMing Cai
Ming Cai
YSYancai Sun
Yancai Sun
As the new year of 2020 approaches, an acute respiratory disease quietly caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), also known as coronavirus disease 2019 (COVID-19) was reported in Wuhan, China. Subsequently, COVID-19 broke out on a global scale and formed a global public health emergency. To date, the destruction that has lasted for more than two years has not stopped and has caused the virus to continuously evolve new mutant strains. SARS-CoV-2 infection has been shown to cause multiple complications and lead to severe disability and death, which has dealt a heavy blow to global development, not only in the medical field but also in social security, economic development, global cooperation and communication. To date, studies on the epidemiology, pathogenic mechanism and pathological characteristics of SARS-CoV-2-induced COVID-19, as well as target confirmation, drug screening, and clinical intervention have achieved remarkable effects. With the continuous efforts of the WHO, governments of various countries, and scientific research and medical personnel, the public’s awareness of COVID-19 is gradually deepening, a variety of prevention methods and detection methods have been implemented, and multiple vaccines and drugs have been developed and urgently marketed. However, these do not appear to have completely stopped the pandemic and ravages of this virus. Meanwhile, research on SARS-CoV-2-induced COVID-19 has also seen some twists and controversies, such as potential drugs and the role of vaccines. In view of the fact that research on SARS-CoV-2 and COVID-19 has been extensive and in depth, this review will systematically update the current understanding of the epidemiology, transmission mechanism, pathological features, potential targets, promising drugs and ongoing clinical trials, which will provide important references and new directions for SARS-CoV-2 and COVID-19 research.

29 January 2022 in Pain and Therapy
Verified
Journal Article
Open access
PDF file
XZXiaowei Zheng
Xiaowei Zheng
HDHaiying Ding
Haiying Ding
SXSilu Xu
Silu Xu
RXRuixiang Xie
Ruixiang Xie
YLYuguo Liu
Yuguo Liu
PHPing Huang
Ping Huang
Introduction Opioid-tolerant patients are more likely to deviate from recommended treatments and to experience inadequate analgesia than opioid-naive ones. The aim of this study was to examine whether pharmacist-led management could help improve treatment adherence and quality of life. Methods Eligible patients were randomized in a 1:1 ratio to control group and intervention group. The control group received routine education and support, while the intervention group received additional individualized pharmacist-led care. The primary endpoint was treatment adherence in the per-protocol analysis, as evaluated by blinded assessors. An interim analysis was planned when 30% patients completed the study. Alpha was divided into the interim analysis (0.015) and the final analysis (0.035). Results In the interim analysis (97 and 87 patients in the control and intervention groups, respectively), the primary endpoint was met. Pharmacist-led intervention significantly increased treatment adherence (93.3 vs. 79.8%; OR: 2.25; 95% CI 1.02, 4.94; P = 0.013), quality of life (0.81 ± 0.17 vs. 0.72 ± 0.25; P = 0.008), and reporting of adverse events (82.7 vs. 61.9%; OR: 1.88; 95% CI 1.16, 3.07; P = 0.004). The two groups did not differ in pain control rate (66.7 vs. 57.1%; OR: 1.25; 95% CI 0.87, 1.78; P = 0.218), breakthrough pain-free rate (66.7 vs. 61.9%; OR: 1.12; 95% CI 0.78, 1.59; P = 0.532) and pain score (1.97 ± 1.04 vs. 2.15 ± 1.24; P = 0.522). Conclusions Pharmacist-led management improved treatment adherence, quality of life, and the reporting of adverse events in opioid-tolerant patients with cancer pain. Trial Registration ClinicalTrials.gov, NCT03455023.

12 May 2021 in Pain Practice
Verified
Journal Article
Closed access
PDF file
HCHuawei Cheng
Huawei Cheng
RZRong Zeng
Rong Zeng
LKLingsuo Kong
Lingsuo Kong
CDConglan Ding
Conglan Ding
YHYifu He
Yifu He
YSYancai Sun
Yancai Sun

1 January 2021 in Annals of Palliative Medicine
Verified
Journal Article
Open access
PDF file
HCHuawei Cheng
Huawei Cheng
HLHongyue Liu
Hongyue Liu
QDQiong Du
Qiong Du
HZHui Zhang
Hui Zhang
XZXiaodan Zhang
Xiaodan Zhang
BYBo Yu
Bo Yu
Efficacy and safety of domestic and imported gefitinib in patients with advanced non-small cell lung cancer Huawei Cheng, Hongyue Liu, Qiong Du, Hui Zhang, Xiaodan Zhang, Yangkui Wang, Jingjing Shao, Feng Yang, Bo Zhang, Jing Shi, Yuguo Liu, Nan Wu, Silu Xu, Qing Wei, Yancai Sun, Qing Zhai, Bo Yu